Phase 2 trial of lenvatinib and everolimus in metastatic renal cell carcinoma - European Medical Journal

Phase 2 trial of lenvatinib and everolimus in metastatic renal cell carcinoma

Oncology
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, James Larkin, FRCP, PhD, of The Royal Marsden, London, UK, discusses the results of a phase 2, three-arm trial of lenvatinib, everolimus, and lenvatinib plus everolimus in patients with metastatic renal cell carcinoma.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now